Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price an opportunity ...

GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...

AnaptysBio’s drug candidates rosnilimab and ANB032 hold key trial results ahead. Find out why ANAB stock is impacted by ...

GSK plc (NYSE:GSK – Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 26,518 call options on the stock. This represents an increase of ...

Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial access—one that ...

A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, ...

The company is pharmaceutical giant GSK (LSE: GSK) and it’s taken a real beating lately. I’ve seen that at first hand, ...

GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant ...

After 24 weeks, GSK saw a statistically significant reduction in monthly itch score in the linerixibat cohort compared to the ...

On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

However, to enhance diversity, companies must adopt a more “youth-ready and youth-friendly approach,” says Matt Lent, chief ...

Since September 2023, GSK's RSV vaccine has been approved in Japan for adults aged 60 and over. The regulatory expansion was supported by results from a global phase III trial. The company noted that, ...